Concepedia

Author

Ellen Wei

Princess Margaret Cancer Centre

Also Known As

Ellen N Wei, Ellen N. Wei, Ellen Nong Wei, Ellen Wei, Ellen nong Wei, WEI, ELLEN

47

Publications

881

Citations

10

H-Index

6

Concepts

All Affiliations

Princess Margaret Cancer CentreUniversity Health NetworkUniversity of TorontoHospital for Sick ChildrenOntario Institute for Cancer Research
EW

About

Ellen Wei is an author at Princess Margaret Cancer Centre specializing in cellular biochemistry, cell biology, and lipid disorders.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

13

2

Cell Biology

1

1

13

3

Cellular Biochemistry

1

1

13

4

Genetics

1

1

13

5

Lipid Disorders

1

1

13

Ellen Wei

×

11

Publications

816

Citations

10

H-Index

YearCitations

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

Suzanne Trudel, Zhihua Li, Ellen Wei,

Blood

2004

288

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

Suzanne Trudel, A. Keith Stewart, Eran Rom,

Blood

2006

140

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Christine I. Chen, P. Leif Bergsagel, Harminder Paul,

Journal of Clinical Oncology

2010

135

MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma

Esther Masih‐Khan, Suzanne Trudel, Carla Heise,

Blood

2006

79

The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades

Yuan Xiao Zhu, Sally J. Benn, Zhihua Li,

The Journal of Experimental Medicine

2004

58

A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).

Christine I. Chen, Harminder Paul, Pantoja Mariela,

Blood

2007

35

Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression

Danielle Croucher, Laura M. Richards, Serges P. Tsofack,

Nature Communications

2021

28

Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium

Suzanne Trudel, Nizar J. Bahlis, Christopher P. Venner,

Blood

2016

20

Murine phosphatidylserine-specific phospholipase A1 (Ps-pla1) maps to Chromosome 16 but is distinct from the lpd (lipid defect) locus

Xiao‐Yan Wen, A. Keith Stewart, Jennifer Skaug,

Mammalian Genome

2001

13

A phase 2 study of ofatumumab (Arzerra<sup>®</sup>) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*

Christine I. Chen, Harminder Paul, Lisa W. Le,

Leukemia & lymphoma/Leukemia and lymphoma

2018

10

Page 1